MENOPUR 1200 iu

Indications

• Gonadotropin replacement therapy
• Treatment of infertility in women with proven hypopituitarism
• Superovulation for assisted conception, such as in vitro fertilization

Dosage

Adults: Initial dosing should be based on serum anti-Müllerian hormone concentration and body weight. Adjust doses according to response, under specialist supervision.

Mechanism of action

Menotrophin works by mimicking the natural hormones FSH and LH, which stimulate the ovaries to produce mature follicles. FSH promotes the growth and maturation of ovarian follicles, while LH triggers ovulation. This coordinated action is essential for the development of eggs and the regulation of the menstrual cycle.

Pharmacodynamics

Menotrophin enhances ovarian response in women undergoing assisted reproductive techniques by facilitating follicular development and maturation. It is crucial in protocols for in vitro fertilization (IVF) as it increases the number of viable oocytes available for retrieval.

Pharmacokinetics

After subcutaneous administration, menotrophin is absorbed into the bloodstream, with peak serum concentrations occurring after a variable time depending on the individual. The elimination half-life is not well-defined, but the hormone activity is generally maintained to support ovarian stimulation over several days. The pharmacokinetics can be influenced by the individual's hormonal status and response to treatment.

Contra-indications

• Mammary carcinoma
• Uterine carcinoma
• Ovarian hyperstimulation syndrome
• Pelvic disorders

Adverse effects

• Fatigue
• Headache
• Nausea
• Gastrointestinal discomfort
• Pelvic pain
• Vomiting
• Thromboembolism
• Ovarian and fallopian tube disorders

Precautions

• Regular monitoring of ovarian response with ultrasound or in combination with serum estradiol levels is required.
• Patients should be advised to withhold hCG and avoid intercourse or use barrier contraceptive methods for at least 4 days if ovarian hyperstimulation syndrome occurs.

Pregnancy

Manufacturer advises to avoid-not indicated during pregnancy.

Breast-feeding

Manufacturer advises to avoid-not indicated during breastfeeding.

Storage

Store in a refrigerator (2°C to 8°C). Do not freeze.

Formulations

• Powder and solvent for solution for injection vials
• Pre-filled disposable injection pens

Indications

• Infertility due to ovarian dysfunction
• Polycystic ovary syndrome (PCOS)
• Assisted reproductive technologies (ART), including in vitro fertilization (IVF)
• Hormonal imbalances affecting menstrual cycles

Dosage

Children: Refer to BNF for Children for specific dosing guidelines related to pediatric patients.

Adults: For fertility treatments, specific dosages of FSH or LH should be determined based on individual patient assessment and response, following established protocols.

Mechanism of action

Follicle development is regulated by the hypothalamic-pituitary-gonadal (HPG) axis. Gonadotropin-releasing hormone (GnRH) from the hypothalamus stimulates the anterior pituitary to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH). FSH promotes the growth and maturation of ovarian follicles, while LH triggers ovulation and the formation of the corpus luteum. Estrogen produced by the growing follicles further regulates the menstrual cycle and reproductive functions.

Pharmacodynamics

The pharmacodynamics of follicle activity involves hormonal regulation and interaction. FSH and LH stimulate ovarian follicles, leading to estrogen production, which has various effects on the reproductive system, including the thickening of the endometrium and regulation of the menstrual cycle. The hormonal feedback mechanisms play a critical role in ensuring proper follicular development and function.

Pharmacokinetics

As follicle development is a physiological process rather than a drug, pharmacokinetics is not applicable. However, in a clinical context, the administration of gonadotropins (like FSH and LH) for fertility treatments would involve understanding their absorption, distribution, metabolism, and excretion. Generally, these hormones are administered via injection, with their effects being immediate and closely monitored during fertility treatments.

Adverse effects

• Ovarian hyperstimulation syndrome
• Multiple pregnancies
• Headaches
• Nausea
• Vomiting
• Abdominal discomfort

Precautions

• Use with caution in patients with a history of ovarian cysts or other ovarian disorders
• Monitor for signs of ovarian hyperstimulation syndrome
• Consider potential for multiple gestation

Pregnancy

Follicle-stimulating hormone (FSH) is used in assisted reproductive technology but should not be used in pregnancy unless clearly needed.

Breast-feeding

There is limited data on the excretion of FSH in breast milk; caution is advised.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Injection solution
• Lyophilized powder for reconstitution

Indications

• Menopausal symptoms (e.g., hot flashes, vaginal dryness)
• Hypogonadism
• Thyroid disorders (e.g., hypothyroidism)
• Adrenal insufficiency
• Growth hormone deficiency
• Polycystic ovary syndrome (PCOS)

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing guidelines, as these depend on the type of hormone and the condition being treated.

Adults: Refer to the specific hormone type and formulation for dosing guidance in adults, as dosages may vary significantly based on individual patient needs and specific conditions being treated.

Mechanism of action

Hormones exert their effects through binding to specific receptors on target cells, initiating a cascade of intracellular signaling pathways. This may involve the activation of gene expression, modulation of enzyme activity, or alteration of cell membrane permeability. The specific mechanism varies depending on the type of hormone and its target tissues.

Pharmacodynamics

Hormones have varied effects depending on their class and the target tissues involved. They can influence metabolic pathways, regulate growth and development, and affect mood and cognition. Hormones typically act through either genomic mechanisms, involving changes in gene transcription, or non-genomic pathways, which may involve rapid signaling via second messengers.

Pharmacokinetics

The pharmacokinetics of hormones vary widely based on their chemical structure, route of administration, and formulation. Generally, hormones are absorbed into circulation after administration, with peak plasma concentrations occurring at variable times depending on the specific hormone. They may be metabolized in the liver or other tissues, with elimination typically occurring through renal or biliary excretion. Half-lives can range from minutes to hours, influencing dosing frequency.

Interactions

• antiepileptics (carbamazepine, eslicarbazepine, fosphenytoin, oxcarbazepine, perampanel, phenobarbital, phenytoin, primidone, rufinamide, topiramate) + hormone replacement therapy: Unknown (decreases effects)
• bosentan + hormone replacement therapy: Unknown (decreases effects)
• ritonavir + hormone replacement therapy: Unknown (decreases effects)
• modafinil + hormone replacement therapy: Unknown (decreases effects)
• rifamycins + hormone replacement therapy: Unknown (decreases effects)
• St John's Wort + hormone replacement therapy: Unknown (decreases efficacy)
• etoricoxib + hormone replacement therapy: Unknown (increases exposure)

Indications

• Hypogonadism in males
• Infertility in females
• Assessment of pituitary function
• Treatment of certain types of precocious puberty

Dosage

Children: Refer to specific clinical guidelines and product information for paediatric dosage recommendations, as they can vary based on the condition being treated.

Adults: Refer to specific clinical guidelines and product information for dosage recommendations, as they can vary based on the condition being treated.

Mechanism of action

Luteinising hormone exerts its effects by binding to specific receptors on the surface of target cells in the ovaries and testes. In females, LH promotes the final maturation of ovarian follicles and triggers ovulation through a surge in hormone levels. In males, LH stimulates Leydig cells in the testes to produce testosterone, which is essential for sperm production and the development of male secondary sexual characteristics.

Pharmacodynamics

The pharmacodynamic effects of luteinising hormone are primarily related to its role in the reproductive hormonal axis. In females, LH levels rise during the luteal phase of the menstrual cycle, leading to ovulation and maintenance of the corpus luteum, which secretes progesterone. In males, LH stimulates testosterone production, which in turn regulates spermatogenesis and influences libido. Dysregulation of LH can lead to various reproductive disorders, including infertility.

Pharmacokinetics

Luteinising hormone has a half-life of approximately 20-30 minutes in the circulation. It is primarily cleared by the kidneys, and its secretion is pulsatile, influenced by gonadotropin-releasing hormone (GnRH) from the hypothalamus. The pharmacokinetics can vary based on the physiological state, such as menstrual cycle phase or age.

Pregnancy

Luteinising hormone is generally not recommended during pregnancy unless specifically indicated, as its effects on pregnancy are not fully understood.

Breast-feeding

The effects of luteinising hormone during breastfeeding are not well established; caution is advised.

Storage

Store in a cool, dry place, away from light. Specific storage conditions may vary depending on the formulation.

Indications

• Attention Deficit Hyperactivity Disorder (ADHD)
• Narcolepsy
• Obesity (as part of a comprehensive weight management program)
• Treatment-resistant depression
• Cognitive enhancement in certain disorders

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines based on age and weight.

Adults: Refer to the specific BNF for individual stimulant medications for appropriate dosing guidelines.

Mechanism of action

Stimulants enhance the release of neurotransmitters such as dopamine and norepinephrine in the brain. They inhibit the reuptake of these neurotransmitters, leading to increased synaptic concentrations and prolonged effects. This mechanism is particularly relevant in the treatment of ADHD, where increased dopamine activity in the prefrontal cortex can improve attention and behavior regulation.

Pharmacodynamics

Stimulants generally exert their effects by increasing neurotransmitter availability in the synaptic cleft, leading to enhanced neuronal firing rates. This results in improved cognitive function, mood elevation, and increased physical activity. The specific pharmacodynamic profile can vary between different stimulant medications, with some exhibiting a more pronounced effect on dopamine versus norepinephrine pathways.

Pharmacokinetics

Stimulants are typically well absorbed in the gastrointestinal tract and may have varying half-lives depending on the formulation (immediate vs extended release). They are metabolized primarily in the liver, and their elimination is often through the kidneys. The onset of action can range from minutes to hours, with effects lasting from a few hours to over 12 hours in some extended-release forms.

Pregnancy

The use of stimulating agents during pregnancy should be approached with caution due to potential risks to fetal development. It is essential to weigh the benefits against possible adverse effects.

Breast-feeding

Caution is advised when using stimulating agents while breastfeeding, as they may pass into breast milk and affect the infant.

Storage

Store in a cool, dry place away from direct sunlight. Ensure the container is tightly closed to maintain stability.